Assessment of platelet activation indices using the ADVIA™ 120 amongst 'high-risk' patients with hypertension
Assessment of platelet activation indices using the ADVIA™ 120 amongst 'high-risk' patients with hypertension
复制标题
DOI：
10.1080/07853890601040063
复制
发表时间：
2007-01-01
影响因子：
4.4
通讯作者：
Lip, Gregory Y. H.
中科院分区：
文献类型：
--
作者：
Boos, Christopher J.;Beevers, Gareth D.;Lip, Gregory Y. H.
背景。血小板活化参与高血压血栓性并发症的发病机制。血小板活化的新替代标志物（平均血小板体积（MPV）、平均血小板成分（MPC，血小板密度的量度）、血小板成分分布宽度（PCDW，血小板形状变化的标志）和血小板团块数量）与心血管风险相关。我们假设这些血小板激活指数在健康对照组（HC, n = 60）、“高危”原发性高血压受试者（HBP, n = 45）和治疗过的既往诊断为恶性期高血压患者（MHT, n = 45）之间逐步增加。在一项横断面研究中，我们使用拜耳ADVIA（TM）血液学系统测量了三个研究组的血小板计数和血小板活化指数（MPV、MPC、PCDW和血小板团块数量）。在三个研究组中，MPV （P = 0.0002）和MPM （P = 0.03）逐渐增加，MPC （P = 0.03）和PCDW （P = 0.001）逐渐减少，尽管血小板计数相似。这些差异仅在健康对照组和MHT组之间有显著差异（事后分析）。多因素分析显示MPV与PCDW （P < 0.0001）、收缩压（P = 0.008）、血小板计数（P < 0.0001）之间存在显著相关（R-2 = 66.5%; P < 0.0001）。尽管血小板计数相似，但随着高血压疾病严重程度的增加，血小板激活指数逐步增加。这可能有助于高血压血栓相关并发症的发病机制。
Background. Platelet activation is involved in the pathogenesis of the thrombotic complications of hypertension. Novel surrogate markers of platelet activation (mean platelet volume (MPV), mean platelet component (MPC, measure of platelet density), platelet component distribution width (PCDW, a marker of platelet shape change) and the number of platelet clumps) have been related to cardiovascular risk. We hypothesized a stepwise increase in these platelet activation indices between healthy controls (HC, n = 60), 'high-risk' essential hypertensive subjects (HBP, n = 45) and treated, previously diagnosed patients with malignant phase hypertension (MHT, n = 45).Methods. In a cross-sectional study, we measured comparative platelet counts and indices of platelet activation (MPV, MPC, PCDW and the number of platelet clumps) using the Bayer ADVIA(TM) haematology system, in our three study groups.Results. There was a stepwise increase in MPV (P = 0.0002) and MPM (P = 0.03), and a stepwise decrease in the MPC (P = 0.03) and PCDW (P = 0.001) across the three study groups, despite similarities in platelet count. These differences were only significantly different (on post-hoc analysis) between the healthy controls and the MHT group. On multivariate analysis, there was a significant relationship (R-2 = 66.5%; P < 0.0001) between the MPV and the PCDW (P < 0.0001), systolic blood pressure (P = 0.008) and platelet count (P < 0.0001).Conclusion. There is a stepwise increase in platelet activation indices, despite similar platelet counts, with increasing severity of hypertensive disease. This may contribute to the pathogenesis of thrombosis-related complications in hypertension.